Danaher Corporation (DHR) reports Q2 2026 earnings: $6.3B revenue, 8% EPS growth, acquisitions, and strong cash flow. Full-year guidance raised.

Key Takeaways

• Revenue reached $6.3 billion, with core revenue up 3% year-over-year, accelerating to 4.5% when excluding respiratory testing.
• Earnings per share (EPS) rose to $1.94, marking an 8% increase year-over-year, leading to raised full-year EPS guidance to $8.45 - $8.60.
• Free cash flow for Q2 was $1.3 billion, with a year-to-date conversion ratio of 124% from net income.
• The acquisition of Masimo closed ahead of schedule, expected to be immediately accretive to EPS, contributing to high single-digit revenue growth.
• Core revenue in high-growth markets increased by over 10%, with notable growth in China and solid performance across the biotechnology segment.

Financial Performance

In the second quarter of 2026, Danaher Corporation reported robust financial results, showcasing a solid performance that exceeded expectations. The company’s revenue totaled $6.3 billion, representing a 3% increase year-over-year. When excluding the impact of respiratory testing, core revenue growth was even stronger at 4.5%, reflecting a 150 basis point acceleration from the first quarter. This growth was bolstered by improved conditions in various end markets, strong commercial execution, and the successful launch of innovative products.

The adjusted diluted net earnings per share for the quarter was $1.94, an 8% increase compared to the previous year. This strong performance prompted Danaher to raise its full-year adjusted EPS guidance to a range of $8.45 to $8.60, up from the prior range of $8.35 to $8.55. The company also reported a gross profit margin of 57.6% and an adjusted operating profit margin of 27.1%, despite slight declines due to lower respiratory revenue.

Strategic Initiatives

Danaher’s strategic focus on innovation and acquisitions has significantly contributed to its strong performance. The successful acquisition of Masimo was completed earlier than anticipated, expected to enhance both strategic positioning and EPS. Masimo is projected to deliver high single-digit revenue growth and has already launched a new AI-enabled product to detect opioid-induced respiratory depression.

Furthermore, Danaher is actively pursuing growth opportunities through other acquisitions, such as the pending acquisition of Stat Lab, a leader in anatomical pathology consumables. Expected to close by the end of 2026, Stat Lab generated approximately $250 million in revenue in 2025 and is projected to grow in the high single digits annually, with a robust recurring revenue model of over 85%.

In terms of product innovation, Danaher highlighted several key advancements across its business segments. For example, in biotechnology, the launch of the Biacor 8S SPR system aims to accelerate drug candidate evaluations. In life sciences, the introduction of the Novus V55 mass spectrometry system enhances analysis capabilities for pharmaceuticals and other applications.

Future Outlook

Looking ahead, Danaher remains optimistic about its growth trajectory. Management anticipates core revenue growth of approximately 2-3% for Q3 2026, with an expected acceleration to mid-single digits by Q4 as the impact from respiratory testing wanes. The full-year outlook for core revenue growth is projected to be in the 3-4% range, driven by strong performances in the life sciences segment and a recovery in academic markets.

The company also noted that its capital deployment strategies remain robust, with a healthy balance sheet that allows for continued investments in innovation and acquisitions. As Danaher navigates through the second half of 2026 and beyond, it is well-positioned to leverage its diversified portfolio and strong market demand to create value for shareholders.

In conclusion, Danaher Corporation’s second-quarter earnings call demonstrated a strong financial performance highlighted by strategic acquisitions and innovative product launches. With a positive outlook for the remainder of the year and the potential for accelerated growth, the company is poised to capitalize on emerging opportunities in its key markets. Investors should find reassurance in Danaher’s strategic initiatives and solid execution as the company continues to drive sustainable long-term value.

This analysis is based on public earnings call materials and is not investment advice.